Hurdles in therapy with regulatory T cells

Piotr Trzonkowski, Rosa Bacchetta, Manuela Battaglia, David Berglund, Hermann Richard Bohnenkamp, Anja Ten Brinke, Andrew Bushell, Nathalie Cools, Edward K. Geissler, Silvia Gregori, S. Marieke Van Ham, Catharien Hilkens, James A. Hutchinson, Giovanna Lombardi, J. Alejandro Madrigal, Natalia Marek-Trzonkowska, Eva M. Martinez-Caceres, Maria Grazia Roncarolo, Silvia Sanchez-Ramon, Aurore SaudemontBirgit Sawitzki

Research output: Contribution to journalArticlepeer-review


Improper activation of the immune system contributes to a variety of clinical conditions, including autoimmune and allergic diseases as well as solid organ and bone marrow transplantation. One approach to counteract this activation is through adoptive therapy with regulatory T cells (Tregs). Ef orts to manufacture these cells have led to good manufacturing practice-compliant protocols, and Treg products are entering early clinical trials. Here, we report the stance of the European Union Cooperation in Science and Technology Action BM1305, "Action to Focus and Accelerate Cell-based Toleranceinducing Therapies-A FACTT?," which identif es hurdles hindering Treg clinical applications in Europe and provides possible solutions.

Original languageEnglish
Article number304ps18
JournalScience Translational Medicine
Issue number304
Publication statusPublished - Sep 9 2015

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Hurdles in therapy with regulatory T cells'. Together they form a unique fingerprint.

Cite this